What are Stelara's Legal Protections Beyond Data Exclusivity?
Stelara (ustekinumab) benefits from multiple layers of legal protection, including patent rights, which extend beyond its initial data exclusivity period. These protections are crucial for maintaining market exclusivity before biosimilars can be introduced.
When Does Stelara's Main Patent Expire?
The primary patent protecting Stelara's active ingredient and its use is set to expire in September 2023 [1]. However, this expiration does not immediately open the door for biosimilars due to additional patent protections.
How Many Patents Protect Stelara?
Stelara is protected by a complex web of patents. While the core composition of matter patent is nearing expiration, numerous secondary patents cover various aspects of the drug, including manufacturing processes, methods of use, and formulations [1]. These secondary patents can significantly extend the effective market exclusivity period for Stelara.
What Are Stelara's Secondary Patents and When Do They Expire?
Beyond the initial patent, Stelara has numerous secondary patents. For instance, a key patent related to a specific method of treating plaque psoriasis is expected to expire in December 2031 [1]. Other patents covering different indications or manufacturing methods have varied expiration dates, some extending into the 2030s [1]. These later-expiring patents are critical in preventing biosimilar entry.
Why are Companies Challenging Stelara's Patents?
Companies developing biosimilars often challenge existing patents to gain earlier market access [2]. These challenges can take the form of invalidity suits or attempts to demonstrate non-infringement. Such legal strategies aim to clear the path for their biosimilar products before the expiry of all relevant patents [2].
Can Biosimilars Be Launched Before All Patents Expire?
Generally, biosimilars cannot be launched until all relevant patents have expired or have been successfully challenged and invalidated [2]. The numerous secondary patents held by the originator company can act as significant barriers, delaying biosimilar entry for years after the initial composition of matter patent expires.
What is the Impact of Biosimilar Competition on Stelara?
The introduction of biosimilars typically leads to significant price reductions and increased market competition [3]. For Stelara, once biosimilars are able to enter the market, patients and healthcare systems are likely to see lower treatment costs.
How Does Stelara Compare to Other Biologics in Terms of Patent Protection?
Biologics like Stelara often have extensive patent portfolios that are strategically layered to maximize market exclusivity [1]. This approach is common in the biopharmaceutical industry, where companies invest heavily in research and development and seek to protect their innovations through a comprehensive patent strategy. Other biologics also face patent challenges from biosimilar developers aiming to shorten exclusivity periods [2].
Where Can I Find More Information on Stelara's Patents?
Detailed information on Stelara's patent landscape, including expiration dates and any ongoing litigation, can be found on specialized databases such as DrugPatentWatch.com [1].
---
Sources:
[1] DrugPatentWatch.com, Stelara (ustekinumab) patents and exclusivity https://drugpatentwatch.com/
[2] Provided information regarding patent challenges.
[3] Provided information regarding the impact of biosimilar competition.